Past Tuesday Talks: What Sets Successful Biotech Companies Apart
Tuesday, May 2, 2023
Presented by Seema Kumar, CEO, Cure
Cure’s CEO, Seema Kumar & Greg Moss, Chief Corporate Strategy & Legal Officer at Evommune, took us through the steps of setting up a biopharma startup’s business strategy and landscape. During this past week’s Tuesday Talk, we discovered the power of building scientific teams vs. non-scientific ones and how this can influence your startup’s culture, investor relations, and even your approach to inevitable successes and failures.
Don’t miss your chance to gain valuable insights into how Evommune is bringing immunology to the forefront by improving patients’ lives beyond their symptoms.
Tuesday Talks:
When: Tuesday, May 2, 4:30 pm – 6:30 pm Where: The rooftop at Cure. 345 Park Avenue South, New York, NY 10010
Topic: A fireside chat with Gregory Moss, Chief Corporate Strategy and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune. Get insight on building scientific teams vs. non-scientific ones and how this can influence your startup’s culture.
Speakers:Greg Moss, Chief Corporate Strategy & Legal Officer at Evommune. Moderated by Seema Kumar, CEO of Cure.
Featured Speakers
About Greg Moss
Gregory S. Moss serves as Chief Corporate Strategy and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, which culminated in Kadmon’s successful $1.9 billion acquisition in late 2021. Mr. Moss helped lead Kadmon’s integration into Sanofi, with broad corporate oversight over legal, compliance, business development, alliance management, human resources, quality assurance, and CMC business functions. During his decade-long tenure at Kadmon, Mr. Moss served in various roles. He was a key strategic partner in financing activities, including the transition from a private to a public company and helping raise more than a billion dollars in debt and equity, and business development efforts, including the spin-off of its gene therapy platform, various international and domestic collaboration and license, co-promotion and distribution agreements, and joint ventures.
About Seema Kumar
Ms. Kumar joins Cure from Johnson & Johnson where she spent nearly 20 years in senior leadership positions, most recently serving as Global Head of the Office of Innovation, Global Health and Scientific Engagement. During her tenure, she led the launch of the company’s Innovation Centers, JLABS and Global Public Health initiatives, as well as the CoLaboratory at the World Economic Forum at Davos and the award winning COVID-19 educational broadcast program, “The Road to a Vaccine.”
